Resminostat is under clinical development by 4SC and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II drugs for Sezary Syndrome have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Resminostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Resminostat overview

Resminostat (4SC-201, YHI-1001, BYK408740) is under development for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides, sezary syndrome, gall bladder cancer, mycosis fungoides and sezary syndrome and pancreatic cancer. It is administered by oral route in the form of film coated tablet. It acts by targeting histone deacetylase I, IIb and IV. The drug candidate is developed based on Virtual High Throughput Screening (vHTS) platform known as 4SCan. It was also under development for the treatment of advanced colorectal cancer, non-small cell lung cancer, replased or refractory Hodgkin's lymphoma, advanced hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma) and other solid tumors.

4SC overview

4SC is a clinical-stage biopharmaceutical company engaged in developing small molecule drugs for the treatment of cancer. The company’s product portfolio focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its small molecule product pipeline comprises of Resminostat for histone deacetylase (HDAC) inhibitor. 4SC’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. The company develops and commercializes its products through partnerships and collaborations with pharmaceutical and biotech companies mainly in the European and Asian markets. 4SC is headquartered in Planegg-Martinsried, Germany.

For a complete picture of Resminostat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.